Brief: Protagonist Reports Positive Results From Phase 1 And Pre-Clinical Studies Of Oral Interleukin-23 Receptor Antagonist JNJ-2113
12/05/2023 14:41
May 12 (Reuters) - Protagonist Therapeutics Inc
PTGX.O :
* PROTAGONIST REPORTS POSITIVE RESULTS FROM PHASE 1 AND
PRE-CLINICAL STUDIES OF ORAL INTERLEUKIN-23 RECEPTOR ANTAGONIST
JNJ-2113
Source text for Eikon: ID:nPn6bv3L7a
Further company coverage: PTGX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary